- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and ...

ZEVASKYN™ shows significant wound healing and pain reduction in RDEB patients, marking a breakthrough treatment option approved by the FDA. ZEVASKYN is the first and only autologous cell-based gene ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...

Skin grafts genetically engineered from a patient’s own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...

This week marked the first time a patient with recessive dystrophic epidermolysis bullosa (RDEB) received prademagene zamikeracel (pz-cel, Zevaskyn), a first-of-its-kind autologous gene therapy to ...